Business
Ceribell sells a point-of-care EEG system for acute-care seizure diagnosis and monitoring, combining portable hardware with AI-powered algorithms.
Ceribell grew FY2025 revenue 36.1%, but losses and negative FCF widened while insiders recorded only sales.
The read at a glance✓ Audited against SEC data
- Business mix — Point-of-care EEGNote
- Revenue — $89.1M, +36.1%OK
- Net income — ($53.4M), loss widenedWatch
- FCF — ($41.6M), -14.3%Watch
- Gross margin — 87.89%, +117 bpsOK
- Insiders — 0 purchases and 42 salesWatch
- Accounting — Altman weak; Beneish clean; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as Ceribell, Inc. reports it. History and quarterly detail are in the app.
- Product$67.3M
- Eeg Recorders And Eeg Headbands$67.3M
- Subscription$21.7M
- Eeg Portal And Clarity Subscriptions$21.7M
Leadership changes
From Ceribell, Inc.'s own filings, the day they're filed.
- Lucian Iancovici · Directors · departureeff. 2025-12-31
- Erica Rogers · director · departureeff. 2025-09-17
- Joseph M. Taylor · director · departure
Latest filings
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-06-02
- 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Ceribell, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.